FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955172389> ?p ?o ?g. }

• W2955172389 endingPage "4766" @default.
• W2955172389 startingPage "4766" @default.
• W2955172389 abstract "Abstract Purpose: Specific cyclin-dependent kinase (CDK) inhibitors are standard of care for patients with metastatic, estrogen receptor-positive (ER+) breast cancer. CDK4/6 inhibitors have improved rates of progression free survival among metastatic, ER+ patients, but resistance limits their clinical efficacy. Various mechanisms of resistance to CDK4/6 inhibitors have been reported, but a comprehensive understanding of this resistance remains elusive. Methods: We generated in vitro models of acquired (AR) and intrinsic (IR) resistance to CDK4/6 inhibitors using ER+ breast cancer cell lines (MCF-7, T47D) cultured with either continuous high dose (500nM) or dose-escalated (50nM to 500nM) CDK4/6 inhibition over three months. RNA expression and gene set enrichment analysis (GSEA) was used to nominate potential pathways associated with AR and IR palbociclib resistance. Reverse phase protein array (RPPA) and western blots were used to measure protein and phosphoprotein levels in CDK4/6 inhibitor resistant cell lines to validate nominated pathways. Cellular proliferation assays were performed to calculate the half-maximal inhibitory concentration (IC50) with inhibitors for CDK4/6 and JAK/STAT. Results: Proliferation assays confirmed that MCF-7 AR and IR cells are resistant to palbociclib (IC50 both &gt;1uM) compared to parental cells (60nM); similar results were observed in the T47D cell lines. Cells resistant to either palbociclib, ribociclib, or abemaciclib demonstrated cross resistance to all three inhibitors. GSEA of transcriptomic data identified 579 genes (from AR cells) and 936 genes (from IR cells) that were differentially expressed between palbociclib-resistant MCF-7s and parental controls. RPPA analyses identified several key pathways that regulate CDK4/6 inhibitor resistance in these models. From GSEA analysis, the interferon (JAK/STAT) signaling pathway was the most differentially expressed pathway identified between palbociclib-resistant and sensitive cells. Western blot analyses showed that baseline expression of phospho-STAT1 is significantly elevated in palbociclib-resistant cells. In cellular proliferation assays, palbociclib-resistant MCF-7s and T47Ds retained sensitivity to JAK/STAT inhibitors like the JAK2-selective compound AZ960. Conclusions: Our data suggests that overactivation of JAK/STAT signaling may be directly involved in the development of CDK4/6 inhibitor resistance in ER-dependent tumors. CDK4/6 inhibitor-resistant cells retain sensitivity to single-agent JAK/STAT inhibition, suggesting that this may be a viable therapeutic option for patients with CDK4/6 inhibitor-resistant ER+ breast cancer. This work was supported in part by 5T32GM007767-40 (Pesch), the Breast Cancer Research Foundation (N003173 to JMR), the UM Rogel Cancer Center and the Taubman Emerging Scholar funds. Citation Format: Andrea M. Pesch, Thomas L. Gonzalez, Benjamin C. Chandler, Siqi Sun, Christina L. Gersch, José M. Larios, Wadie S. David, Corey W. Speers, James M. Rae. Transcriptomic profiling reveals a potential role for JAK/STAT inhibition in CDK4/6 inhibitor-resistant, ER+ breast cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4766." @default.
• W2955172389 created "2019-07-12" @default.
• W2955172389 creator A5005010217 @default.
• W2955172389 creator A5005345083 @default.
• W2955172389 creator A5025450175 @default.
• W2955172389 creator A5029911377 @default.
• W2955172389 creator A5030088447 @default.
• W2955172389 creator A5047365376 @default.
• W2955172389 creator A5052071953 @default.
• W2955172389 creator A5067053763 @default.
• W2955172389 creator A5074374139 @default.
• W2955172389 date "2019-07-01" @default.
• W2955172389 modified "2023-09-27" @default.
• W2955172389 title "Abstract 4766: Transcriptomic profiling reveals a potential role for JAK/STAT inhibition in CDK4/6 inhibitor-resistant, ER+ breast cancers" @default.
• W2955172389 doi "https://doi.org/10.1158/1538-7445.am2019-4766" @default.
• W2955172389 hasPublicationYear "2019" @default.
• W2955172389 type Work @default.
• W2955172389 sameAs 2955172389 @default.
• W2955172389 citedByCount "1" @default.
• W2955172389 countsByYear W29551723892020 @default.
• W2955172389 crossrefType "journal-article" @default.
• W2955172389 hasAuthorship W2955172389A5005010217 @default.
• W2955172389 hasAuthorship W2955172389A5005345083 @default.
• W2955172389 hasAuthorship W2955172389A5025450175 @default.
• W2955172389 hasAuthorship W2955172389A5029911377 @default.
• W2955172389 hasAuthorship W2955172389A5030088447 @default.
• W2955172389 hasAuthorship W2955172389A5047365376 @default.
• W2955172389 hasAuthorship W2955172389A5052071953 @default.
• W2955172389 hasAuthorship W2955172389A5067053763 @default.
• W2955172389 hasAuthorship W2955172389A5074374139 @default.
• W2955172389 hasConcept C104317684 @default.
• W2955172389 hasConcept C121608353 @default.
• W2955172389 hasConcept C124320809 @default.
• W2955172389 hasConcept C150194340 @default.
• W2955172389 hasConcept C162317418 @default.
• W2955172389 hasConcept C2775930923 @default.
• W2955172389 hasConcept C2779707156 @default.
• W2955172389 hasConcept C2779744173 @default.
• W2955172389 hasConcept C29537977 @default.
• W2955172389 hasConcept C502942594 @default.
• W2955172389 hasConcept C530470458 @default.
• W2955172389 hasConcept C54355233 @default.
• W2955172389 hasConcept C62112901 @default.
• W2955172389 hasConcept C84606932 @default.
• W2955172389 hasConcept C86803240 @default.
• W2955172389 hasConceptScore W2955172389C104317684 @default.
• W2955172389 hasConceptScore W2955172389C121608353 @default.
• W2955172389 hasConceptScore W2955172389C124320809 @default.
• W2955172389 hasConceptScore W2955172389C150194340 @default.
• W2955172389 hasConceptScore W2955172389C162317418 @default.
• W2955172389 hasConceptScore W2955172389C2775930923 @default.
• W2955172389 hasConceptScore W2955172389C2779707156 @default.
• W2955172389 hasConceptScore W2955172389C2779744173 @default.
• W2955172389 hasConceptScore W2955172389C29537977 @default.
• W2955172389 hasConceptScore W2955172389C502942594 @default.
• W2955172389 hasConceptScore W2955172389C530470458 @default.
• W2955172389 hasConceptScore W2955172389C54355233 @default.
• W2955172389 hasConceptScore W2955172389C62112901 @default.
• W2955172389 hasConceptScore W2955172389C84606932 @default.
• W2955172389 hasConceptScore W2955172389C86803240 @default.
• W2955172389 hasIssue "13_Supplement" @default.
• W2955172389 hasLocation W29551723891 @default.
• W2955172389 hasOpenAccess W2955172389 @default.
• W2955172389 hasPrimaryLocation W29551723891 @default.
• W2955172389 hasRelatedWork W2015277722 @default.
• W2955172389 hasRelatedWork W2341704440 @default.
• W2955172389 hasRelatedWork W2622670954 @default.
• W2955172389 hasRelatedWork W2731600971 @default.
• W2955172389 hasRelatedWork W2784856005 @default.
• W2955172389 hasRelatedWork W2799966561 @default.
• W2955172389 hasRelatedWork W2981795130 @default.
• W2955172389 hasRelatedWork W4206711305 @default.
• W2955172389 hasRelatedWork W4282937607 @default.
• W2955172389 hasRelatedWork W4323058812 @default.
• W2955172389 hasVolume "79" @default.
• W2955172389 isParatext "false" @default.
• W2955172389 isRetracted "false" @default.
• W2955172389 magId "2955172389" @default.
• W2955172389 workType "article" @default.